10.61

2.75% -0.28

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $10.61, with a volume of 301.24K. It is down -2.75% in the last 24 hours and down -6.61% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$10.89

Open:

$10.96

24h Volume:

301.24K

Relative Volume:

0.38

Market Cap:

$605.06M

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-3.9887

EPS:

-2.66

Net Cash Flow:

$-78.56M

1W Performance:

+4.96%

1M Performance:

-6.61%

6M Performance:

+203.44%

1Y Performance:

+38.98%

1-Day Range:

$10.54

$11.12

1-Week Range:

$10.09

$11.30

52-Week Range:

$2.235

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1138)

Industry

Biotechnology (635)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

227

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	10.59	622.20M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	429.20	107.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	781.88	80.03B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	431.18	57.37B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	908.04	55.83B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	207.44	44.13B	447.02M	-1.18B	-906.14M	-6.1812

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

Nov 23, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2025

Nov 21, 2025

Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - MarketScreener

Nov 21, 2025

4D Molecular Therapeutics taps Kristian Humer as CFO - MSN

Nov 21, 2025

Nov 20, 2025

Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat

Nov 20, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat

Nov 20, 2025

4D Molecular Therapeutics (NASDAQ: FDMT) to join Evercore Healthcare Conference fireside chat - Stock Titan

Nov 20, 2025

Nov 19, 2025

4d Molecular Therapeutics chief legal officer sells $17k in stock - Investing.com Canada

Nov 19, 2025

[Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity - Stock Titan

Nov 19, 2025

4D Molecular Therapeutics Executive Sells Shares - TradingView

Nov 19, 2025

Officer Bizily Sells 1,635 ($17.3K) Of 4D Molecular Therapeutics Inc [FDMT] - TradingView

Nov 19, 2025

Published on: 2025-11-19 17:30:27 - newser.com

Nov 19, 2025

Nov 18, 2025

Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Nov 18, 2025

4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - MSN

Nov 18, 2025

What recovery options are there for 4D Molecular Therapeutics Inc.July 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com

Nov 18, 2025

FDMT: 4D-150 achieves up to 92% injection reduction in wet AMD, with global phase III trials underway - TradingView

Nov 18, 2025

FDMT: 4D-150 gene therapy offers up to 92% injection reduction and strong safety for retinal disease - TradingView

Nov 18, 2025

Nov 17, 2025

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer By Investing.com - Investing.com Nigeria

Nov 17, 2025

4D Molecular Therapeutics Names Kristian Humer as CFO - MarketScreener

Nov 17, 2025

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer - Investing.com

Nov 17, 2025

4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer - Quiver Quantitative

Nov 17, 2025

[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event | FDMT SEC FilingForm 8-K - Stock Titan

Nov 17, 2025

4D Molecular Therapeutics (Nasdaq: FDMT) names Kristian Humer CFO to lead finance - Stock Titan

Nov 17, 2025

Nov 16, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen - MarketBeat

Nov 16, 2025

Nov 15, 2025